TY - JOUR AU - Bailey, S. R. AU - Nelson, M. H. AU - Majchrzak, K. AU - Bowers, J. S. AU - Wyatt, M. M. AU - Smith, A. S. PY - 2017 DA - 2017// TI - Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-01867-9 DO - 10.1038/s41467-017-01867-9 ID - Bailey2017 ER - TY - JOUR AU - Najjar, Y. G. AU - Menk, A. V. AU - Sander, C. AU - Rao, U. AU - Karunamurthy, A. AU - Bhatia, R. PY - 2019 DA - 2019// TI - Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma JO - JCI Insight. VL - 4 UR - https://doi.org/10.1172/jci.insight.124989 DO - 10.1172/jci.insight.124989 ID - Najjar2019 ER - TY - JOUR AU - Fischer, G. M. AU - Jalali, A. AU - Kircher, D. A. PY - 2019 DA - 2019// TI - Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1489 DO - 10.1158/2159-8290.CD-18-1489 ID - Fischer2019 ER - TY - JOUR AU - Ascierto, P. A. AU - Bono, P. AU - Bhatia, S. AU - Melero, I. AU - Nyakas, M. S. AU - Svane, I. PY - 2017 DA - 2017// TI - Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in Pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx440 DO - 10.1093/annonc/mdx440 ID - Ascierto2017 ER - TY - JOUR AU - Heinhuis, K. M. AU - Carlino, M. AU - Joerger, M. AU - Nicola, M. AU - Meniawy, T. AU - Rottey, S. PY - 2019 DA - 2019// TI - Tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors: a phase 1/2a dose-escalation and cohort-expansion clinical trial JO - JAMA Oncol. UR - https://doi.org/10.1001/jamaoncol.2019.3848 DO - 10.1001/jamaoncol.2019.3848 ID - Heinhuis2019 ER - TY - JOUR AU - Butterfield, L. H. AU - Comin-Anduix, B. AU - Vujanovic, L. AU - Lee, Y. AU - Dissette, V. B. AU - Yang, J. Q. PY - 2008 DA - 2008// TI - Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma JO - J Immunother VL - 31 UR - https://doi.org/10.1097/CJI.0b013e31816a8910 DO - 10.1097/CJI.0b013e31816a8910 ID - Butterfield2008 ER - TY - JOUR AU - Butterfield, L. H. AU - Vujanovic, L. AU - Santos, P. M. AU - Maurer, D. M. AU - Gambotto, A. AU - Lohr, J. PY - 2019 DA - 2019// TI - Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0552-x DO - 10.1186/s40425-019-0552-x ID - Butterfield2019 ER - TY - STD TI - Santos PM, Adamik J, Howes TR, Du S, Vujanovic, Warren S, et al. Impact of checkpoint blockade on cancer vaccine activated CD8+ T cell responses. J Exper Med. 2020 (in press). ID - ref8 ER - TY - STD TI - Maurer DM, Adamik J, Santos PM, Shi J, Shurin MR, Kirkwood JM, et al. Dysregulated NFκB-dependent ICOSL expression in human dendritic cell vaccines impairs T cell responses in melanoma patients. 2020 (in revision). ID - ref9 ER - TY - JOUR AU - Ott, P. A. AU - Hu, Z. AU - Keskin, D. B. AU - Shukla, S. A. AU - Sun, J. AU - Bozym, D. J. PY - 2017 DA - 2017// TI - An immunogenic personal neoantigen vaccine for patients with melanoma JO - Nature VL - 547 UR - https://doi.org/10.1038/nature22991 DO - 10.1038/nature22991 ID - Ott2017 ER - TY - JOUR AU - Gettinger, S. AU - Borghaei, H. AU - Brahmer, J. AU - Chow, L. AU - Burgio, M. AU - Castro, J. PY - 2019 DA - 2019// TI - Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLCOA14.04 JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.08.486 DO - 10.1016/j.jtho.2019.08.486 ID - Gettinger2019 ER - TY - JOUR AU - Champiat, S. AU - Dercle, L. AU - Ammari, S. AU - Massard, C. AU - Hollebecque, A. AU - Postel-Vinay, S. PY - 2017 DA - 2017// TI - Hyperprogressive disease is a new pattern of progression in cancer patients treated with anti-PD-1/PD-L1 JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1741 DO - 10.1158/1078-0432.CCR-16-1741 ID - Champiat2017 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2019 DA - 2019// TI - Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.00149 DO - 10.1200/JCO.18.00149 ID - Reck2019 ER - TY - JOUR AU - Mok, T. S. K. AU - Wu, Y. L. AU - Kudaba, I. AU - Kowalski, D. M. AU - Cho, B. C. AU - Turna, H. Z. PY - 2019 DA - 2019// TI - Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial JO - Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32409-7 DO - 10.1016/S0140-6736(18)32409-7 ID - Mok2019 ER - TY - JOUR AU - Spigel, D. AU - Marinis, F. AU - Giaccone, G. AU - Reinmuth, N. AU - Vergnenegre, A. AU - Barrios, C. H. PY - 2019 DA - 2019// TI - IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz293 DO - 10.1093/annonc/mdz293 ID - Spigel2019 ER - TY - JOUR AU - Gandhi, L. AU - Rodríguez-Abreu, D. AU - Gadgeel, S. AU - Esteban, E. AU - Felip, E. AU - Angelis, F. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Paz-Ares, L. AU - Luft, A. AU - Vicente, D. AU - Tafreshi, A. AU - Gümüş, M. AU - Mazières, J. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810865 DO - 10.1056/NEJMoa1810865 ID - Paz-Ares2018 ER - TY - JOUR AU - West, H. AU - McCleod, M. AU - Hussein, M. AU - Morabito, A. AU - Rittmeyer, A. AU - Conter, H. J. PY - 2019 DA - 2019// TI - Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30167-6 DO - 10.1016/S1470-2045(19)30167-6 ID - West2019 ER - TY - JOUR AU - Socinski, M. A. AU - Jotte, R. M. AU - Cappuzzo, F. AU - Orlandi, F. AU - Stroyakovskiy, D. AU - Nogami, N. PY - 2018 DA - 2018// TI - Atezolizumab for first-line treatment of metastatic nonsquamous NSCLCy JO - N Engl J Med. VL - 378 UR - https://doi.org/10.1056/NEJMoa1716948 DO - 10.1056/NEJMoa1716948 ID - Socinski2018 ER - TY - STD TI - Papadimitrakopoulou VA, Cobo M, Bordoni R, et al. IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Presented at WCLC 2018 Abstract OA05.07 ID - ref21 ER - TY - JOUR AU - Jotte, R. M. AU - Reck, M. AU - Shankar, G. AU - Lee, A. AU - Coleman, S. AU - McCleland, M. PY - 2020 DA - 2020// TI - Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations JO - Expert Rev Respir Med. VL - 14 UR - https://doi.org/10.1080/17476348.2020.1701439 DO - 10.1080/17476348.2020.1701439 ID - Jotte2020 ER - TY - JOUR AU - Hellmann, M. D. AU - Paz-Ares, L. AU - Bernabe Caro, R. AU - Zurawski, B. AU - Kim, S. W. AU - Carcereny Costa, E. PY - 2019 DA - 2019// TI - Nivolumab plus ipilimumab in advanced non-small-cell lung cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1910231 DO - 10.1056/NEJMoa1910231 ID - Hellmann2019 ER - TY - JOUR AU - Skinner, H. D. AU - Giri, U. AU - Yang, L. P. AU - Kumar, M. AU - Liu, Y. AU - Story, M. D. PY - 2017 DA - 2017// TI - Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2586 DO - 10.1158/1078-0432.CCR-16-2586 ID - Skinner2017 ER - TY - JOUR AU - Jie, H. B. AU - Schuler, P. J. AU - Lee, S. C. AU - Srivastava, R. M. AU - Argiris, A. AU - Ferrone, S. PY - 2015 DA - 2015// TI - CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-2788 DO - 10.1158/0008-5472.CAN-14-2788 ID - Jie2015 ER - TY - JOUR AU - Shayan, G. AU - Kansy, B. A. AU - Gibson, S. P. AU - Srivastava, R. M. AU - Bryan, J. K. AU - Bauman, J. E. PY - 2018 DA - 2018// TI - Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-0357 DO - 10.1158/1078-0432.CCR-17-0357 ID - Shayan2018 ER - TY - JOUR AU - Ferris, R. L. AU - Gonçalves, A. AU - Baxi, S. S. AU - Martens, U. M. AU - Gauthier, H. AU - Langenberg, M. PY - 2017 DA - 2017// TI - An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN) JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx440.041 DO - 10.1093/annonc/mdx440.041 ID - Ferris2017 ER - TY - JOUR AU - Huang, R. Y. AU - Eppolito, C. AU - Lele, S. AU - Shrikant, P. AU - Matsuzaki, J. AU - Odunsi, K. PY - 2015 DA - 2015// TI - LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4751 DO - 10.18632/oncotarget.4751 ID - Huang2015 ER - TY - JOUR AU - Huang, R. Y. AU - Francois, A. AU - McGray, A. R. AU - Miliotto, A. AU - Odunsi, K. PY - 2016 DA - 2016// TI - Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2016.1249561 DO - 10.1080/2162402X.2016.1249561 ID - Huang2016 ER - TY - JOUR AU - Mistarz, A. AU - Komorowski, M. P. AU - Graczyk, M. A. AU - Gil, M. AU - Jiang, A. AU - Opyrchal, M. PY - 2019 DA - 2019// TI - Recruitment of intratumoral CD103+ dendritic cells by a CXCR4 antagonist-armed virotherapy enhances antitumor immunity JO - Mol Ther Oncol VL - 14 UR - https://doi.org/10.1016/j.omto.2019.06.003 DO - 10.1016/j.omto.2019.06.003 ID - Mistarz2019 ER - TY - JOUR AU - Cortés, J. AU - Lipatov, O. AU - Im, S. -. A. AU - Gonçalves, A. AU - Lee, K. S. AU - Schmid, P. PY - 2019 DA - 2019// TI - KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz394.010 DO - 10.1093/annonc/mdz394.010 ID - Cortés2019 ER - TY - JOUR AU - Emens, L. A. AU - Cruz, C. AU - Eder, J. P. AU - Braiteh, F. AU - Chung, C. AU - Tolaney, S. M. PY - 2019 DA - 2019// TI - Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study JO - JAMA Oncol VL - 5 UR - https://doi.org/10.1001/jamaoncol.2018.4224 DO - 10.1001/jamaoncol.2018.4224 ID - Emens2019 ER - TY - JOUR AU - Schmid, P. AU - Adams, S. AU - Rugo, H. S. AU - Schneeweiss, A. AU - Barrios, C. H. AU - Iwata, H. PY - 2018 DA - 2018// TI - Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809615 DO - 10.1056/NEJMoa1809615 ID - Schmid2018 ER - TY - STD TI - Emens LA, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, et al. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Presented at the 2018 San Antonio Breast Cancer Symposium. https://www.sabcs.org/SABCS/2018/AllAbstracts_2018-12-03_Updated.pdf. Abstract GS1-04. UR - https://www.sabcs.org/SABCS/2018/AllAbstracts_2018-12-03_Updated.pdf ID - ref34 ER - TY - JOUR AU - Schmid, P. AU - Cortés, J. AU - Dent, R. AU - Pusztai, L. AU - McArthur, H. L. AU - Kuemmel, S. PY - 2019 DA - 2019// TI - KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz394.003 DO - 10.1093/annonc/mdz394.003 ID - Schmid2019 ER - TY - JOUR AU - Eggermont, A. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2016 DA - 2016// TI - Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611299 DO - 10.1056/NEJMoa1611299 ID - Eggermont2016 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2019 DA - 2019// TI - Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial JO - Eur J Cancer VL - 119 UR - https://doi.org/10.1016/j.ejca.2019.07.001 DO - 10.1016/j.ejca.2019.07.001 ID - Eggermont2019 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Blank, C. U. AU - Mandala, M. AU - Long, G. V. AU - Atkinson, V. AU - Dalle, S. PY - 2018 DA - 2018// TI - Adjuvant pembrolizumab versus placebo in resected stage III melanoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1802357 DO - 10.1056/NEJMoa1802357 ID - Eggermont2018 ER - TY - JOUR AU - Weber, J. AU - Mandala, M. AU - Vecchio, M. AU - Gogas, H. J. AU - Arance, A. M. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709030 DO - 10.1056/NEJMoa1709030 ID - Weber2017 ER - TY - JOUR AU - Weber, J. AU - Mandala, M. AU - Vecchio, M. AU - Gogas, H. J. AU - Arance, A. M. AU - Cowey, C. L. PY - 2019 DA - 2019// TI - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: updated results from a phase III trial (CheckMate 238) JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.9502 DO - 10.1200/JCO.2018.36.15_suppl.9502 ID - Weber2019 ER - TY - JOUR AU - Owen, C. N. AU - Larkin, J. M. G. AU - Shoushtari, A. N. AU - Carlino, M. S. AU - Blank, C. U. AU - Lee, B. PY - 2019 DA - 2019// TI - A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.9502 DO - 10.1200/JCO.2019.37.15_suppl.9502 ID - Owen2019 ER - TY - JOUR AU - Larkin, J. M. G. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Rutkowski, P. AU - Lao, C. PY - 2019 DA - 2019// TI - 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO + IPI) combination therapy in advanced melanoma JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz394.065 DO - 10.1093/annonc/mdz394.065 ID - Larkin2019 ER - TY - JOUR AU - Weber, J. S. AU - Vecchio, M. AU - Mandala, M. AU - Gogas, H. AU - Arance, A. M. AU - Dalle, S. PY - 2019 DA - 2019// TI - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz255 DO - 10.1093/annonc/mdz255 ID - Weber2019 ER - TY - JOUR AU - Vanpouille-Box, C. AU - Diamond, J. M. AU - Pilones, K. A. AU - Zavadil, J. AU - Babb, J. S. AU - Formenti, S. C. PY - 2015 DA - 2015// TI - TGFβ is a master regulator of radiation therapy-induced antitumor immunity JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3511 DO - 10.1158/0008-5472.CAN-14-3511 ID - Vanpouille-Box2015 ER - TY - JOUR AU - Formenti, S. C. AU - Lee, P. AU - Adams, S. AU - Goldberg, J. D. AU - Li, X. AU - Xie, M. W. PY - 2018 DA - 2018// TI - Focal irradiation and systemic TGFβ blockade in metastatic breast cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3322 DO - 10.1158/1078-0432.CCR-17-3322 ID - Formenti2018 ER - TY - JOUR AU - Dewan, M. Z. AU - Galloway, A. E. AU - Kawashima, N. PY - 2009 DA - 2009// TI - Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-0265 DO - 10.1158/1078-0432.CCR-09-0265 ID - Dewan2009 ER - TY - JOUR AU - Luke, J. J. AU - Lemons, J. M. AU - Karrison, T. G. AU - Pitroda, S. P. AU - Melotek, J. M. AU - Zha, Y. PY - 2018 DA - 2018// TI - Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.2229 DO - 10.1200/JCO.2017.76.2229 ID - Luke2018 ER - TY - JOUR AU - Nanda, R. AU - Liu, M. C. AU - Yau, C. AU - Asare, S. AU - Hylton, N. AU - Van't Veer, L. PY - 2017 DA - 2017// TI - Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.506 DO - 10.1200/JCO.2017.35.15_suppl.506 ID - Nanda2017 ER - TY - JOUR AU - Nghiem, P. T. AU - Bhatia, S. AU - Lipson, E. J. AU - Kudchadkar, R. R. AU - Miller, N. J. AU - Annamalai, L. PY - 2016 DA - 2016// TI - PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1603702 DO - 10.1056/NEJMoa1603702 ID - Nghiem2016 ER - TY - JOUR AU - Nghiem, P. T. AU - Bhatia, S. AU - Lipson, E. J. AU - Sharfman, W. H. AU - Kudchadkar, R. R. AU - Friedlander, P. A. PY - 2018 DA - 2018// TI - Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.9506 DO - 10.1200/JCO.2018.36.15_suppl.9506 ID - Nghiem2018 ER - TY - STD TI - Topalian SL, Bhatia S, Hollebecque A, Awada A, De Boer JP, Kudchadkar RR, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res 2017;77(13 Suppl): Abstract CT074. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR. ID - ref51 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. S. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - D'Angelo, S. P. PY - 2018 DA - 2018// TI - Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-017-0310-x DO - 10.1186/s40425-017-0310-x ID - Kaufman2018 ER - TY - STD TI - D’Angelo SP, Bhatia S, Brohl AS, Hamid O. Mehnert JM, Terheyden P, et al. Efficacy and safety of avelumab in patients with previously treated metastatic Merkel cell carcinoma: 3-year follow-up from part A of the phase 2 JAVELIN Merkel 200 trial. Presented at the International Symposium on Merkel Cell Carcinoma, October 21–22, 2019, Tampa, FL, USA. ID - ref53 ER - TY - JOUR AU - D'Angelo, S. P. AU - Russell, J. AU - Lebbé, C. AU - Chmielowski, B. AU - Gambichler, T. AU - Grob, J. J. PY - 2018 DA - 2018// TI - Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.0077 DO - 10.1001/jamaoncol.2018.0077 ID - D'Angelo2018 ER - TY - JOUR AU - Ascierto, P. A. AU - Nathan, P. AU - Kasturi, V. AU - Dirix, L. Y. AU - Fenig, E. AU - Hennessy, M. PY - 2018 DA - 2018// TI - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP) JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy487.010 DO - 10.1093/annonc/mdy487.010 ID - Ascierto2018 ER - TY - JOUR AU - Patnaik, A. AU - Swanson, K. D. AU - Csizmadia, E. AU - Solanki, A. AU - Landon-Brace, N. AU - Gehring, M. P. PY - 2017 DA - 2017// TI - Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-0778 DO - 10.1158/2159-8290.CD-16-0778 ID - Patnaik2017 ER - TY - JOUR AU - Robinson, D. AU - Allen, E. M. AU - Wu, Y. M. PY - 2015 DA - 2015// TI - Integrative clinical genomics of advanced prostate cancer [published correction appears in Cell. 2015 Jul 16;162(2):454] JO - Cell VL - 161 UR - https://doi.org/10.1016/j.cell.2015.05.001 DO - 10.1016/j.cell.2015.05.001 ID - Robinson2015 ER - TY - JOUR AU - Abida, W. AU - Patnaik, A. AU - Campbell, D. PY - 2020 DA - 2020// TI - Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration [published online ahead of print, 2020 Aug 14] JO - J Clin Oncol. UR - https://doi.org/10.1200/JCO.20.01035 DO - 10.1200/JCO.20.01035 ID - Abida2020 ER - TY - JOUR AU - Bono, J. AU - Mateo, J. AU - Fizazi, K. PY - 2020 DA - 2020// TI - Olaparib for metastatic castration-resistant prostate cancer JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1911440 DO - 10.1056/NEJMoa1911440 ID - Bono2020 ER - TY - JOUR AU - Pantelidou, C. AU - Sonzogni, O. AU - Oliveria, T. M. PY - 2019 DA - 2019// TI - PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1218 DO - 10.1158/2159-8290.CD-18-1218 ID - Pantelidou2019 ER - TY - JOUR AU - Ding, L. AU - Kim, H. J. AU - Wang, Q. PY - 2018 DA - 2018// TI - PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer JO - Cell Rep VL - 25 UR - https://doi.org/10.1016/j.celrep.2018.11.054 DO - 10.1016/j.celrep.2018.11.054 ID - Ding2018 ER - TY - JOUR AU - Dougan, M. PY - 2017 DA - 2017// TI - Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01547 DO - 10.3389/fimmu.2017.01547 ID - Dougan2017 ER - TY - JOUR AU - Beck, K. E. AU - Blansfield, J. A. AU - Tran, K. Q. PY - 2006 DA - 2006// TI - Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.5716 DO - 10.1200/JCO.2005.04.5716 ID - Beck2006 ER - TY - JOUR AU - Faje, A. T. AU - Lawrence, D. AU - Flaherty, K. AU - Freedman, C. AU - Fadden, R. AU - Rubin, K. PY - 2018 DA - 2018// TI - High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma JO - Cancer VL - 124 UR - https://doi.org/10.1002/cncr.31629 DO - 10.1002/cncr.31629 ID - Faje2018 ER - TY - JOUR AU - Arriola, E. AU - Wheater, M. AU - Karydis, I. AU - Thomas, G. AU - Ottensmeier, C. PY - 2015 DA - 2015// TI - Infliximab for IPILIMUMAB-related colitis-letter JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-2471 DO - 10.1158/1078-0432.CCR-15-2471 ID - Arriola2015 ER - TY - JOUR AU - Bertrand, F. AU - Montfort, A. AU - Marcheteau, E. PY - 2017 DA - 2017// TI - TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-02358-7 DO - 10.1038/s41467-017-02358-7 ID - Bertrand2017 ER - TY - JOUR AU - Hughes, M. S. AU - Molina, G. E. AU - Chen, S. T. AU - Zheng, H. AU - Deshpande, V. AU - Fadden, R. PY - 2019 DA - 2019// TI - Budesonide treatment for microscopic colitis from immune checkpoint inhibitors JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0756-0 DO - 10.1186/s40425-019-0756-0 ID - Hughes2019 ER - TY - JOUR AU - Yau, T. AU - Park, J. W. AU - Finn, R. S. AU - Cheng, A. -. L. AU - Mathurin, P. AU - Edeline, J. PY - 2019 DA - 2019// TI - CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz394.029 DO - 10.1093/annonc/mdz394.029 ID - Yau2019 ER - TY - JOUR AU - Finn, R. S. AU - Ryoo, B. -. Y. AU - Merle, P. AU - Kudo, M. AU - Bouattour, M. AU - Lim, H. -. Y. PY - 2019 DA - 2019// TI - Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC) JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.4004 DO - 10.1200/JCO.2019.37.15_suppl.4004 ID - Finn2019 ER - TY - JOUR AU - Finn, R. S. AU - Qin, S. AU - Ikeda, M. AU - Galle, P. R. AU - Ducreux, M. AU - Kim, T. PY - 2020 DA - 2020// TI - Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1915745 DO - 10.1056/NEJMoa1915745 ID - Finn2020 ER - TY - STD TI - Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, et al. A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results [abstract]. Cancer Res 2019;79(13 Suppl): Abstract CT061. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR. ID - ref71 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. AU - Halwani, A. AU - Scott, E. C. AU - Gutierrez, M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Younes, A. AU - Santoro, A. AU - Shipp, M. AU - Zinzani, P. L. AU - Timmerman, J. M. AU - Ansell, S. PY - 2016 DA - 2016// TI - Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30167-X DO - 10.1016/S1470-2045(16)30167-X ID - Younes2016 ER - TY - JOUR AU - Ansell, S. M. AU - Minnema, M. C. AU - Johnson, P. AU - Timmerman, J. M. AU - Armand, P. AU - Shipp, M. A. PY - 2019 DA - 2019// TI - Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, Phase II study JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.00766 DO - 10.1200/JCO.18.00766 ID - Ansell2019 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. AU - Lekakis, L. J. AU - Miklos, D. B. AU - Jacobson, C. A. PY - 2017 DA - 2017// TI - Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Schuster, S. J. AU - Bishop, M. R. AU - Tam, C. S. AU - Waller, E. K. AU - Borchmann, P. AU - McGuirk, J. P. PY - 2019 DA - 2019// TI - Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1804980 DO - 10.1056/NEJMoa1804980 ID - Schuster2019 ER - TY - JOUR AU - Abramson, J. S. AU - Palomba, M. L. AU - Arnason, J. E. AU - Lunning, M. A. AU - Solomon, S. R. AU - Farazi, T. PY - 2019 DA - 2019// TI - Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: initial results from TRANSCEND NHL 001 JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.7515 DO - 10.1200/JCO.2019.37.15_suppl.7515 ID - Abramson2019 ER - TY - STD TI - Wang ML, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study. Abstract #754. Presented at the 2019 ASH Annual Meeting, December 9, 2019; Orlando, FL. ID - ref78 ER - TY - JOUR AU - Timmerman, J. M. AU - Steward, K. K. AU - Yamada, R. E. AU - Young, P. A. AU - Minning, D. M. AU - Sachdev, R. K. PY - 2015 DA - 2015// TI - Antibody-interferon-alpha fusion protein therapy for the treatment of B-cell non-Hodgkin lymphoma: enhanced ADCC, inhibition of proliferation, and in vivo eradication of CD20+ human lymphomas JO - Blood VL - 126 UR - https://doi.org/10.1182/blood.V126.23.2762.2762 DO - 10.1182/blood.V126.23.2762.2762 ID - Timmerman2015 ER - TY - JOUR AU - Mangino, M. AU - Roederer, M. AU - Beddall, M. H. AU - Nestle, F. O. AU - Spector, T. D. PY - 2017 DA - 2017// TI - Innate and adaptive immune traits are differentially affected by genetic and environmental factors JO - Nat Commun. VL - 8 UR - https://doi.org/10.1038/ncomms13850 DO - 10.1038/ncomms13850 ID - Mangino2017 ER - TY - JOUR AU - Orru, V. AU - Steri, M. AU - Sole, G. AU - Sidore, C. AU - Virdis, F. AU - Dei, M. PY - 2013 DA - 2013// TI - Genetic variants regulating immune cell levels in health and disease JO - Cell VL - 155 UR - https://doi.org/10.1016/j.cell.2013.08.041 DO - 10.1016/j.cell.2013.08.041 ID - Orru2013 ER - TY - JOUR AU - Roederer, M. AU - Quaye, L. AU - Mangino, M. AU - Beddall, M. H. AU - Mahnke, Y. AU - Chattopadhyay, P. PY - 2015 DA - 2015// TI - The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis JO - Cell VL - 161 UR - https://doi.org/10.1016/j.cell.2015.02.046 DO - 10.1016/j.cell.2015.02.046 ID - Roederer2015 ER - TY - JOUR AU - Qu, K. AU - Zaba, L. C. AU - Giresi, P. G. AU - Li, R. AU - Longmire, M. AU - Kim, Y. H. AU - Greenleaf, W. J. AU - Chang, H. Y. PY - 2015 DA - 2015// TI - Individuality and variation of personal regulomes in primary human T cells JO - Cell Syst VL - 1 UR - https://doi.org/10.1016/j.cels.2015.06.003 DO - 10.1016/j.cels.2015.06.003 ID - Qu2015 ER - TY - JOUR AU - Chat, V. AU - Ferguson, R. AU - Simpson, D. AU - Kazlow, E. AU - Lax, R. AU - Moran, U. PY - 2019 DA - 2019// TI - Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition JO - Cancer Immunol Immunother VL - 68 UR - https://doi.org/10.1007/s00262-019-02318-8 DO - 10.1007/s00262-019-02318-8 ID - Chat2019 ER - TY - JOUR AU - Vogelsang, M. AU - Martinez, C. N. AU - Rendleman, J. AU - Bapodra, A. AU - Malecek, K. AU - Romanchuk, A. AU - Kazlow, E. AU - Shapiro, R. L. AU - Berman, R. S. AU - Krogsgaard, M. AU - Osman, I. AU - Kirchhoff, T. PY - 2016 DA - 2016// TI - The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2066 DO - 10.1158/1078-0432.CCR-15-2066 ID - Vogelsang2016 ER - TY - JOUR AU - Fuertes, M. B. AU - Kacha, A. K. AU - Kline, J. AU - Woo, S. R. AU - Kranz, D. M. AU - Murphy, K. M. PY - 2011 DA - 2011// TI - Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells JO - J Exp Med VL - 208 UR - https://doi.org/10.1084/jem.20101159 DO - 10.1084/jem.20101159 ID - Fuertes2011 ER - TY - JOUR AU - Andtbacka, R. H. AU - Kaufman, H. L. AU - Collichio, F. AU - Amatruda, T. AU - Senzer, N. AU - Chesney, J. PY - 2015 DA - 2015// TI - Talimogene laherparepvec improves durable response rate in patients with advanced melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3377 DO - 10.1200/JCO.2014.58.3377 ID - Andtbacka2015 ER - TY - JOUR AU - Zamarin, D. AU - Holmgaard, R. B. AU - Subudhi, S. K. AU - Park, J. S. AU - Mansour, M. AU - Palese, P. PY - 2014 DA - 2014// TI - Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008095 DO - 10.1126/scitranslmed.3008095 ID - Zamarin2014 ER - TY - JOUR AU - Agrawal, N. AU - Bettegowda, C. AU - Cheong, I. AU - Geschwind, J. F. AU - Drake, C. G. AU - Hipkiss, E. L. PY - 2004 DA - 2004// TI - Bacteriolytic therapy can generate a potent immune response against experimental tumors JO - Proc Natl Acad Sci USA VL - 101 UR - https://doi.org/10.1073/pnas.0406242101 DO - 10.1073/pnas.0406242101 ID - Agrawal2004 ER - TY - JOUR AU - Roberts, N. J. AU - Zhang, L. AU - Janku, F. AU - Collins, A. AU - Bai, R. Y. AU - Staedtke, V. PY - 2014 DA - 2014// TI - Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses JO - Sci Transl Med. VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008982 DO - 10.1126/scitranslmed.3008982 ID - Roberts2014 ER - TY - JOUR AU - Janku, F. AU - Gounder, M. AU - Pezeshki, A. M. AU - Murthy, R. AU - Wang-Gillam, A. AU - Shepard, D. PY - 2019 DA - 2019// TI - First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors: safety, activity, and immune responses abstract JO - Cancer Immunol Res VL - 7 UR - https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A011 DO - 10.1158/2326-6074.CRICIMTEATIAACR18-A011 ID - Janku2019 ER - TY - JOUR AU - Verma, V. AU - Shrimali, R. K. AU - Ahmad, S. AU - Dai, W. AU - Wang, H. AU - Lu, S. PY - 2019 DA - 2019// TI - PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1 + CD38hi cells and anti-PD-1 resistance JO - Nat Immunol VL - 20 UR - https://doi.org/10.1038/s41590-019-0441-y DO - 10.1038/s41590-019-0441-y ID - Verma2019 ER - TY - JOUR AU - Shrimali, R. K. AU - Ahmad, S. AU - Verma, V. AU - Zeng, P. AU - Ananth, S. AU - Gaur, P. PY - 2017 DA - 2017// TI - Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-17-0292 DO - 10.1158/2326-6066.CIR-17-0292 ID - Shrimali2017 ER -